Phaseline

Targets › TOP2B

TOP2B (DNA topoisomerase 2-beta): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 2 Phase 2, 1 Phase 3, 1 Phase 4; Oncology; next expected readout Oct 2027.

Key decatenating enzyme that alters DNA topology by binding to two double-stranded DNA molecules, generating a double-stranded break in one of the strands, passing the intact strand through the broken strand, and religating the broken strand. Plays a role in B-cell differentiation. (UniProt, Q02880)

Open in Phaseline: the race on TOP2B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hospital JP GarrahanESHAP
Combination chemotherapy: Etoposide (topoisomerase II inhibitor), Methylprednisolone (cort
TOP2B, NR3C1Phase 4Pediatric Hodgkin's DiseaseOct 2027
Stichting Hemato-Oncologie voor Volwassenen NederlandDexrazoxane
DNA topoisomerase II inhibitor
TOP2A, TOP2BPhase 3DLBCL - Diffuse Large B Cell LymphomaDec 2028
M.D. Anderson Cancer CenterDexrazoxane Hydrochloride
DNA topoisomerase II inhibitor
TOP2A, TOP2BPhase 2Acute Myeloid LeukemiaDec 2027
CNS PharmaceuticalsBerubicin
DNA topoisomerase II inhibitor
TOP2A, TOP2BPhase 2Glioblastoma Multiforme, Adult–

Conditions

Glioblastoma Multiforme, Adult (1) Acute Myeloid Leukemia (1) DLBCL - Diffuse Large B Cell Lymphoma (1) Pediatric Hodgkin's Disease (1)

Modalities

small molecule (2), mixed (2)

Companies

CNS Pharmaceuticals (1) M.D. Anderson Cancer Center (1) Stichting Hemato-Oncologie voor Volwassenen Nederland (1) Hospital JP Garrahan (1)

Related targets

TOP2A (3) NR3C1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.